For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$54.04
Thesis
Tempus AI builds a multimodal clinical and molecular data platform spanning diagnostics, genomic sequencing, and data licensing. Its scaled real-world datasets support both precision diagnostics and AI-enabled drug discovery partnerships.
Catalysts
- Genomics and diagnostics testing volume growth
- Data-licensing and pharma partnership expansion
- Margin progression as the platform scales
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 18DealSEC
8-K filed with items 1.01 and 9.01 disclosing entry into material definitive agreement.
- Nov 2Financial resultsSEC
Tempus AI files 8-K (items 2.02,7.01,9.01) reporting results of operations and financial condition.
- Oct 23OtherSEC
Filed 8-K item 8.01 other events disclosure.
- Oct 21Securities offeringSEC
Tempus AI filed Form 424B3 prospectus supplement with the SEC on 2026-10-21.
- Oct 20M&ASEC
Amended S-4 filing for securities issued in business combination.
- Oct 2M&ASEC
S-4/A amendment to registration statement for proposed business combination filed.
- Sep 15M&ASEC
SEC Form 425 filing related to business combination.
- Aug 31M&ASEC
S-4 registration statement filed for merger or acquisition transaction.